Perspectives
"Proposals on healthcare reforms in Japan last week, suggest a severe price cut in April 2010 and significant changes in the pricing policy of long-listed drugs. These developments may mean a difficult path for generic companies in particular and all companies with high long-listed drug exposure in general. We discuss the implications for key japanese companies in this report." ... Read more
16 Nov 2009 | From the latest Perspectives entry by Devesh Singh, Japan’s New Government Signals Diminishing Outlook for Generics
Research Library . Recent Updates
| 8 Dec 2009 | SUN PHARMA-Upgrade to Outperform - Para IVs Galore - High Probability and Underappreciated » |
|---|---|
| 29 Nov 2009 | RBXY Not Rated - Launch of Valtrex – Much Needed Boost for RBXY » |
| 26 Nov 2009 | Novartis-Outperform, Incyte-Outperform - Partnership With Incyte: We like the deal » |
| 26 Nov 2009 | Incyte -Outperform, Novartis -Outperform - Incyte JAK Delivers a Jack Pot » |
| 26 Nov 2009 | Rising Stars Theme Report - ABLX, IMMU, MOR, TRBN, SGEN, GEN, HGSI, IMGN, MITI, XOMA, CRXLM, DYAX, R » |
| 20 Nov 2009 | ISIS - Outperform - Establishing Safety of 2nd-Generation Antisense Oligonucleotide is the Key » |
